(NASDAQ: VTRS) Viatris's forecast annual revenue growth rate of 2.55% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 9.01%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.75%.
Viatris's revenue in 2026 is $14,562,600,000.On average, 13 Wall Street analysts forecast VTRS's revenue for 2026 to be $17,554,466,706,396, with the lowest VTRS revenue forecast at $16,728,798,874,710, and the highest VTRS revenue forecast at $18,261,350,167,374. On average, 13 Wall Street analysts forecast VTRS's revenue for 2027 to be $17,934,110,871,600, with the lowest VTRS revenue forecast at $16,997,810,537,784, and the highest VTRS revenue forecast at $18,748,133,176,746.
In 2028, VTRS is forecast to generate $18,281,147,562,492 in revenue, with the lowest revenue forecast at $17,024,595,248,826 and the highest revenue forecast at $19,382,814,373,176.